BioFocus, a subsidiary of Galapagos, has entered into a collaboration agreement with Boehringer Ingelheim to apply its drug discovery services to an undisclosed target within BI’s drug discovery portfolio.
 
David Smith, chief executive officer of Galapagos Services, said, “We are delighted to have secured this contract with Boehringer Ingelheim, one of the world’s leading research-based pharmaceutical companies and a new integrated drug discovery client to BioFocus.  It is testament to the strength and depth of BioFocus’ drug discovery capabilities and expertise in this particular gene family.”